Theresa E Singleton, PhD

Greater Boston Area (617) 599-4138 (cell) theresa@singletonscience.com www.singletonscience.com www.linkedin.com/in/singletonscience

SCIENTIFIC WRITER & EDITOR

- Owner/Principal Scientific Writer at Singleton Science, LLC
- PhD-trained biologist with extensive experience in the creation of accurate, science-rich content
- Editor/proofreader with sharp attention to detail
- Specializations: Plain language writing and editing, Health literacy

PROFESSIONAL DEVELOPMENT

Advanced Workshops

- o Reporting Risks, Rates, and Ratios, American Medical Writers Association
- o Understanding Sample Size and Study Power, American Medical Writers Association

Certificates

- o Evidence-Based Medicine, American Medical Writers Association
- Statistics in Medicine, Stanford University
- Writing in the Sciences, Stanford University
- o Essential Skills, American Medical Writers Association

EDUCATION

PhD, Boston University, Graduate School of Medical Sciences, Boston, MA, 2006

Specializations: Microbiology, Immunology

Research Interests: Dendritic Cell Biology, Host-Pathogen Interactions, Infectious Diseases,

Vaccine Adjuvants

BS, Cornell University, College of Human Ecology, Ithaca, NY, 1997

Specialization: Nutritional Science

PROFESSIONAL EXPERIENCE

Owner and Principal Scientific Writer, 2013 - present

Singleton Science, LLC, Beverly, MA

- Write and edit the following documents:
 - Plain language communications including brochures, newsletters, FAQs, patient profiles, website articles, and clinical trial summaries
 - Research manuscripts for submission to peer-reviewed journals
 - Scientific congress abstracts and posters
 - Advisory board meeting executive summaries
 - White papers

Scientific Writer and Editor. 2011 - 2013

Cell Signaling Technology, Marketing Communications, Danvers, MA

- Carried out substantive editing of in-house research manuscripts, which were published in Nature Biotechnology
- Maintained consistency of editorial style across marketing collateral
- Developed educational materials for global sales force including monthly product summary reports and new hire training presentations and webinars
- Created and reviewed scientific product literature including datasheets, brochures, inserts, and flyers
- Wrote content for customer-facing promotional eBlasts and website landing pages

Ruth L. Kirschstein Postdoctoral Research Fellow, 2006 - 2010

Children's Hospital, Division of Gastroenterology, Boston, MA

Research Interests: Allergy, Fc Receptor Biology, Mucosal Immunology

- Wrote manuscript, which was published in Molecular Immunology
- Edited manuscripts for grammar and scientific clarity
- Secured research funding through grantsmanship
- Proofread and edited four NIH grant applications
- Gave oral and poster presentations on research findings

VOLUNTEER EXPERIENCE

At Large Director, 2016 - 2019

American Medical Writers Association

- Served as full voting member of the Board of Directors
- Served as board liaison for the AMWA Journal
- Served as chair and board liaison of the Member Recognition Committee

President, 2014 - 2015

American Medical Writers Association, New England Chapter

- Led the President-Elect to successful management of chapter programs
- o Served as chair of the Executive Council
- Served as liaison between the chapter and national organization
- o Communicated with chapter members through monthly eNews

President-Elect/Program Director, 2013 - 2014

American Medical Writers Association, New England Chapter

- Managed chapter programs: recruited event speakers, negotiated venue bookings, wrote meeting announcements
- Served as chair of the Nominating Committee
- Served as chapter delegate at national Board of Directors meetings

Peer Reviewer, AMWA Journal, 2011 - 2014

American Medical Writers Association

Periodically reviewed manuscripts for the Science Series

RESEARCH AWARDS

Ruth L. Kirschstein National Research Service Award, 2008 - 2010

Title: FcεRI as a receptor for antigen surveillance at mucosal surfaces

Harvard Medical School Fellowship in Pediatric Gastroenterology and Nutrition, 2006 - 2007, Title: Training in pediatric gastroenterology and nutrition

Research Supplement for Underrepresented Minorities, 2003 - 2006

Title: Neisserial porins and antigen presenting cells

PUBLICATIONS

As writer and substantive editor

Cornely OA, File TM, Garrity-Ryan L, Chitra S, Noble R, McGovern PC. 2021. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment. International Journal of Antimicrobial Agents 57:106263

Kovacs SJ, Ting L, Praestgaard J, Sunkara G, Sun H, Stein DS, et al. 2020. *An open-label study of the impact of hepatic impairment on the pharmacokinetics and safety of single oral and intravenous doses of omadacycline*. Antimicrobial Agents and Chemotherapy 64:e01650-20

Strauch J, Braun TM, Short H. 2020. *Use of an automated hand hygiene compliance system by emergency room nurses and technicians is associated with decreased employee absenteeism.*American Journal of Infection Control 48:575-577

Karlowsky JA, Steenbergen J, Zhanel GG. 2019. *Microbiology and preclinical review of omadacycline*. Clinical Infectious Diseases 69:S6-S15

Ramirez JA, Tzanis E, Curran M, Noble R, Chitra S, Manley A, et al. 2019. *Early clinical response in community-acquired bacterial pneumonia: from clinical endpoint to clinical practice*. Clinical Infectious Diseases 69:S33-S39

McCalla S, Reilly M, Thomas R, McSpedon-Rai D, McMahon LA, Palumbo M. 2018. *An automated hand hygiene compliance system is associated with decreased rates of health care-associated infections*. American Journal of Infection Control 46:1381-1386

Daveson AJM, Ee HC, Andrews JM, King T, Goldstein KE, Dzuris JL, et al. 2017. *Epitope-specific immunotherapy targeting CD4-positive T cells in celiac disease: safety, pharmacokinetics, and effects on intestinal histology and plasma cytokines with escalating dose regimens of Nexvax2 in a randomized, double-blind, placebo-controlled phase 1 study.* EBioMedicine 26:78-90

Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH. 2016. *Ridinilazole: a novel therapy for Clostridium difficile infection*. International Journal of Antimicrobial Agents 48:137-143

Yurkovetskiy AV, Yin M, Bodyak N, Stevenson CA, Thomas JD, Hammond CE, et al. 2015. *A polymer-based antibody-vinca drug conjugate platform: characterization and preclinical efficacy.* Cancer Research 75:3365-3372

As substantive editor

Yurkovetskiy AV, Bodyak ND, Yin M, Thomas JD, Clardy SM, Conlon PR, et al. 2021. *Dolaflexin: a novel antibody-drug conjugate platform featuring high drug loading and a controlled bystander effect.* Molecular Cancer Therapeutics 20:885-895

Cheung WC, Beausoleil SA, Zhang X, Sato S, Schieferl SM, Wieler JS, et al. 2012. *A proteomics approach for the identification and cloning of monoclonal antibodies from serum*. Nature Biotechnology 30:447-452

Sato S, Beausoleil SA, Popova L, Beaudet JG, Ramenani RK, Zhang X, et al. 2012. *Proteomics-directed cloning of circulating antiviral human monoclonal antibodies*. Nature Biotechnology 30:1039-1043

As author

Singleton TE, Platzer B, Dehlink E, Fiebiger E. 2009. The first transmembrane region of the β-chain stabilizes the tetrameric FcεRI complex. Molecular Immunology 46:2333-2339

<u>Singleton TE</u>, Massari P, Wetzler LM. 2005. *Neisserial porin-induced dendritic cell activation is MyD88 and TLR2 dependent*. Journal of Immunology 174:3545-3550

Papernik LA, Bethea AS, <u>Singleton TE</u>, Magalhaes JV, Garvin DF, Kochian LV. 2001. Physiological basis of reduced Al tolerance in ditelosomic lines of Chinese Spring wheat. Planta 212:829-834